Furthermore, they found that patients with gliomas harboring IDH mutations had improved survival compared to those without, with median overall survival (OS) over twice as long in those with IDH mutations compared to those without within glioblastoma and within grade 3 astrocytomas [10]. Here, IDH2 is linked to central nervous system cancer.